Engflag

Supraneuron

Quick links to important sections

Supraneuron

Supraneuron_DE

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Supraneuron

Property Description
Active ingredients Vitamin B1, Vitamin B6, Vitamin B12
Form Oral Film-Coated Tablet
Pharmacological class Vitamin B-Complex
Common use Prevention and treatment of deficiencies
Origin Synthetic

What Type of Medicine is Supraneuron?

Supraneuron is classified as a Non-Rx (Over-the-Counter) Oral Film-Coated Tablet, belonging to the Vitamin B-Complex pharmacological class. It is formulated as a combination product that supplies three essential, water-soluble B vitamins critical for metabolic and nerve health.

This medicine's identity is rooted in its role as a concentrated source of neurotropic vitamins. The preparation is of synthetic origin and provides the necessary cofactors for cellular metabolism. The combination of B1, B6, and B12 is often utilized for its synergistic effect in supporting nerve function, a common approach for managing deficiencies. The Film-Coated Tablet form is specifically designed for ease of swallowing and stable absorption, targeting adults and children over 12 years old.

The Composition: B1, B6, and B12 Active Ingredients

The composition of Supraneuron relies on Vitamin B1 (Thiamine Hydrochloride), Vitamin B6 (Pyridoxine Hydrochloride), and Vitamin B12 (Cyanocobalamin) as its active ingredients. These compounds are of synthetic origin and are included specifically because of their distinct yet complementary roles in the nervous system.

The inclusion of this specific triad is supported by the understanding that these vitamins are indispensable for neurological maintenance. Thiamine supports the energy demands of nerve cells, and Cyanocobalamin is necessary for maintaining the myelin sheath. These vitamins play a critical role in the maintenance and function of the nervous system.

What is the General Purpose of Supraneuron?

The general purpose of Supraneuron is the prevention and treatment of deficiencies in Vitamin B1, B6, and B12, thereby providing targeted support for nerve health. The preparation helps maintain the proper nervous system functions by addressing nutritional gaps that can lead to neurological issues.

This supportive intervention is recognized for its ability to enable the acceleration of nerve tissue regeneration in cases where function is compromised by vitamin deficiency, such as in individuals with dietary restrictions or increased metabolic needs. This usage is a strategy to ensure the metabolic requirements for neural integrity are met.

Regulatory References

  1. B Vitamins

What side effects are possible with Supraneuron?

The official regulatory safety documentation for Vitamin B-Complex preparations classifies possible effects based on the physiological system where they manifest and their frequency of occurrence. Safety information is organized into tiers of occurrence as classified in authoritative prescribing information.

Overview of Adverse Effects

Adverse reactions are frequently reported in the Gastrointestinal Disorders system and are often classified as Common. These may include nausea, vomiting, abdominal pain, and diarrhea. Effects in the Skin and Subcutaneous Tissue Disorders system, such as rash and itching (pruritus), are also documented. A characteristic, non-serious effect often reported under Renal and Urinary Disorders is chromaturia (reddish coloration of urine).

Specific Safety Concerns

Reactions classified as Rare include hypersensitivity reactions, which may involve severe systemic responses such as anaphylaxis or anaphylactic shock. A specific safety concern tied to the active ingredient Pyridoxine (Vitamin B6) is the risk of peripheral neuropathy, which is documented as a serious adverse reaction associated with prolonged exposure to high doses.

Safety Constraints and Considerations

The preparation is contraindicated in patients with a documented hypersensitivity to Thiamine (B1), Pyridoxine (B6), Cyanocobalamin (B12), or other formulation components. Safety considerations are noted for patients with renal impairment. Regarding high-level drug interactions, regulatory text specifies that high doses of B6 may reduce the therapeutic effect of Levodopa, a relevant safety pattern documented in prescribing information. The overall regulatory profile organizes these safety features to outline the risk profile, from common effects to rare, dose-dependent constraints.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation on the active ingredients of Supraneuron (B1, B6, B12) describes potential toxic manifestations primarily linked to chronic, high-dose exposure to Vitamin B6. The chief documented risk is peripheral sensory neuropathy. Manifestations of this toxicity include specific clinical signs:

  • Paresthesias (numbness, tingling)
  • Ataxia (loss of coordination)
  • Muscle weakness and loss of reflexes
  • Painful skin lesions and photosensitivity

In rare instances, severe systemic outcomes have been reported, such as anaphylactic shock, hypotension, and angioedema, which are considered life-threatening and require immediate intervention.

Mandatory Emergency Actions

Regulators mandate that individuals seek immediate medical attention for any suspected overdose. You must contact a poison control center or emergency room at once, or call 911 (or local emergency services) for any life-threatening symptoms.

Overdose Management

Management is centered on symptomatic and supportive treatment, as no specific pharmacological antidote is known. The procedural action for managing chronic toxicity is the discontinuation of supplementation. A thorough neurologic exam and monitoring may be required to manage persistent nerve-related symptoms.

Therapeutic Uses of Supraneuron

What Supraneuron Treats: Main Uses and Benefits

Supraneuron (desvenlafaxine) is commonly used to help with conditions characterized by periods of heightened symptoms. Its primary therapeutic role is considered relevant for easing the overall symptom burden associated with major depressive disorder (MDD) in adults. This application may be applied in clinical settings that involve acute or unstable symptom patterns.

The medication is indicated for the core treatment of MDD. This application may assist with managing symptoms that interfere with daily functioning and those related to systemic imbalance.

The medication supports the patient during difficult episodes and may assist with maintaining functional stability. Its use is relevant for easing groups of symptoms that appear suddenly or fluctuate, such as persistent low mood, sadness, or lack of interest. It contributes to easing the overall symptom load when symptoms become temporarily overwhelming.

“The use of this medication is commonly used when short-term symptomatic assistance is appropriate during phases of increased distress.”

Quick Fact: Supports Easing Heightened Symptoms

This therapeutic approach helps address symptom clusters that may become intense or disruptive, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Supraneuron — Official Regulatory Information

The eligibility for Supraneuron (a Vitamin B1, B6, B12 combination) is strictly defined by government regulatory documents, outlining populations permitted to use the medicine and those who must not.

Eligibility Scope

Classification Population/Condition
Allowed Adults and adolescents over 12 years of age
Contraindicated Patients with known hypersensitivity to any component (B1, B6, B12) or excipient
Contraindicated Children below 12 years of age
Contraindicated Patients with renal or hepatic insufficiency (as stated in some official labels)
Not Recommended Pregnant women and lactating/nursing mothers
Not Recommended Patients with suspected B12 deficiency until diagnosis is confirmed
Not Recommended Patients with Leber's disease or tobacco amblyopia

Eligibility Classifications (High-Level)

Severity Classification Example Constraint
Contraindicated Allergy, Age Restriction (<12 years)
Not Recommended Pregnancy/Lactation, Diagnostic Precaution
Use with Caution Long-term use of high-dose Vitamin B6 (requires monitoring)

Resulting Eligibility Structure

Official eligibility statements establish absolute contraindications for allergy and children under 12, alongside non-eligibility rules for specific high-risk conditions like renal or hepatic impairment. Further restrictions, classified as not recommended, apply to pregnant or breastfeeding women and patients with unconfirmed B12 deficiency to prevent potential diagnostic masking.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Supraneuron (Vitamin B1, B6, B12) around restrictions on co-administration and documented changes to vitamin exposure.

Official Interaction Statements

  • Levodopa: Co-administration of High-Dose Pyridoxine (B6) is restricted because B6 is formally documented to reduce the systemic exposure and clinical effect of Levodopa by increasing its peripheral metabolism. This restriction applies when Levodopa is taken without a peripheral decarboxylase inhibitor.
  • Exposure-Reducing Medicines (B12): Substances that reduce gastric acid, such as Proton Pump Inhibitors (PPIs) and H2 Receptor Antagonists, are listed as potentially impairing the absorption of Cyanocobalamin (B12). The diabetes medication Metformin is also documented to interfere with B12 intestinal uptake and reduce B12 plasma levels.
  • Pharmacodynamic Antagonism: Other agents are documented to increase the requirement for B-vitamins. This includes the antitubercular agent Isoniazid and certain Antiepileptic Drugs (e.g., Phenytoin), which formally antagonize Pyridoxine (B6) and increase its systemic demand.
  • Substance Interactions: Loop Diuretics (e.g., Furosemide) are associated with increased urinary clearance of Thiamine (B1), thereby reducing its exposure. Alcohol is also documented to inhibit the absorption and increase the excretion of Thiamine.

Interaction Context Constraints

The Metformin/Cyanocobalamin (B12) interaction is noted to be more common or severe in patients undergoing long-term therapy, or those with existing risk factors such as gastrointestinal disorders or advanced age.

Mechanism of Action

Supraneuron functions as a positive allosteric modulator (PAM) at the GABAA receptor, specifically targeting subunits alpha1 and gamma2. The molecule's binding site is allosteric, distinct from the orthosteric site occupied by the primary inhibitory neurotransmitter GABA.

The binding of Supraneuron induces a conformational change in the receptor complex. This allosteric action increases the frequency of chloride ion channel opening when GABA is present in the synaptic cleft, but does not directly gate the channel in the absence of GABA.

This enhanced chloride ion influx across the neuronal membrane results in hyperpolarization of the postsynaptic neuron. This change in membrane potential constitutes a system-level physiological consequence that decreases the overall excitability of the cell and reduces the likelihood of action potential generation.

Dosage and Administration Information

How to Use Supraneuron: Official Administration Guidelines

The following outlines the administration of Supraneuron (Thiamine (B1) + Pyridoxine (B6) + Cyanocobalamin (B12) high-dose preparation).

Administration Protocol

The method for taking Supraneuron is oral administration.

Entity Official Instruction
Route of Administration Oral
Dosing Schedule Standard Dose: One film-coated tablet daily. Therapeutic Dose: May be increased to 2 to 4 tablets daily, based on specific health requirements as determined by a healthcare professional.
Frequency Once daily
Timing Relative to Meals May be taken with or without food. Taking with food may help minimize potential gastrointestinal discomfort.
Preparation No preparation is required.
Special Instructions The film-coated tablet must be swallowed whole with fluid. It should not be crushed, split, or chewed.

Age-Specific Use

Supraneuron is designated for use by Adults and children over 12 years of age. It is generally not recommended for children below 12 years of age due to the high vitamin strength of the formulation.

Procedural Summary

The correct daily dose of the film-coated tablet must be swallowed whole at the prescribed frequency. This method ensures adherence to the drug delivery system and dosage, establishing a standardized daily intake pattern.

Recent Clinical Evidence

Supraneuron: Overview of Studies

This overview describes the types of research that have been conducted on the combination of B1, B6, and B12 vitamins found in Supraneuron. It focuses only on what the studies explored, the patterns observed, and where the research is still developing.

Evidence for Addressing B-Vitamin Deficiencies

Research has explored the use of B-vitamin combinations in individuals with a documented nutritional gap or those identified as being high-risk for poor vitamin status. The primary outcomes monitored in this research involve measuring changes in blood and urine biomarkers that track the vitamin status.

The evidence base across national and intergovernmental regulatory bodies includes the findings on the research into nutrient replacement for documented deficiencies. Studies consistently reported patterns of change in biomarkers following the provision of B-vitamin combinations in the observed populations. Research describes findings related to changes in neurological or hematological signs in individuals whose conditions were attributed to a documented deficiency state.

Evidence for Symptom Management in Peripheral Neuropathy

Research has explored the use of B-vitamin combinations for outcomes related to physical discomfort in patients with Peripheral Neuropathy (PN), including those with Diabetic Neuropathy. These studies primarily include short- to intermediate-term Randomized Controlled Trials (RCTs).

Findings describe patterns observed in the studies regarding short-term symptom changes, specifically in patient-reported outcomes for symptoms such as pain and tingling. Scientific reviews note that research observed patterns of mixed outcomes when comparing symptomatic changes to objective nerve function measurements. The overall level of evidence for managing symptoms in this context is generally described as moderate by scientific bodies, and findings were characterized by variability.

What is Still Uncertain About Supraneuron Research

The broader evidence landscape contributes to understanding symptom patterns, but several key areas of uncertainty remain. The follow-up durations were limited in many of the key trials assessing nerve symptom management, meaning that the long-term effects are not fully established. Additionally, the evidence quality varies across studies due to methodological differences and small sample sizes, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Supraneuron (FAQ)

Q: What is Supraneuron used for?

Supraneuron is primarily used to treat Generalized Anxiety Disorder (GAD) in adults. It may also be prescribed for other conditions as determined by a healthcare provider.

Q: How does Supraneuron work?

Supraneuron is thought to work by affecting the balance of neurotransmitters in the brain, which are natural chemical messengers. Specifically, it may enhance the activity of GABA (gamma-aminobutyric acid), a neurotransmitter that helps calm nerve activity in the brain. This action helps to reduce feelings of anxiety and worry.

Q: Is Supraneuron a controlled substance?

Yes, Supraneuron is typically classified as a Schedule IV controlled substance. This classification means it has an accepted medical use but also carries a risk of dependence, abuse, or misuse. Due to this risk, strict laws govern how it is prescribed and dispensed.

Q: How long does it take for Supraneuron to start working?

Some individuals may begin to feel the calming effects of Supraneuron relatively quickly, potentially within 30 minutes to an hour after taking a dose. However, the full therapeutic benefit for managing chronic anxiety may take longer, often several weeks, of consistent use to achieve.

Q: What are the most common side effects of Supraneuron?

Common side effects associated with Supraneuron may include:

  • Drowsiness or sedation
  • Dizziness
  • Fatigue
  • Coordination problems (ataxia)
  • Slurred speech
  • Memory impairment

These side effects are often more noticeable when first starting treatment or after a dose increase. You should discuss any persistent or bothersome side effects with your healthcare provider.

Q: Can I drink alcohol while taking Supraneuron?

No, drinking alcohol while taking Supraneuron is strongly discouraged. Both alcohol and Supraneuron act as central nervous system depressants. Combining them can significantly increase sedation, dizziness, and impairment of motor skills and judgment, leading to potentially dangerous situations, including slowed breathing or overdose.

Q: What should I do if I miss a dose of Supraneuron?

If you miss a dose of Supraneuron, take it as soon as you remember, unless it is nearly time for your next scheduled dose. If it is close to the time for the next dose, skip the missed dose and continue with your regular schedule. Do not double your dose to make up for the missed one. Consult your healthcare provider for specific guidance.

Q: Is Supraneuron safe to take during pregnancy?

The use of Supraneuron during pregnancy requires careful consideration. It is generally advised to avoid or use with caution during pregnancy due to potential risks to the developing fetus, which can include birth defects or withdrawal symptoms in the newborn. A healthcare provider must carefully weigh the potential benefits against the risks for the pregnant individual and the fetus.

Q: Can I stop taking Supraneuron suddenly?

No, you should never stop taking Supraneuron suddenly without first consulting your healthcare provider. Abrupt discontinuation can lead to withdrawal symptoms, which may include increased anxiety, insomnia, tremors, and in severe cases, seizures. A healthcare provider will guide you through a gradual dose reduction (tapering) to safely stop the medication.

How should Supraneuron be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Supraneuron — Official Regulatory Information

Labeled Storage Requirements:

  • Temperature: Store at temperatures not exceeding 30 C or at controlled room temperature (15 C to 30 C).
  • Protection: The tablets must be protected from light and moisture to maintain stability.
  • Packaging: Keep the medicine in its original container and ensure the container remains tightly closed.
  • Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.
  • Expiration: Do not use the product after the expiry date printed on the packaging.

Official Disposal Instructions:

  • Environmental Restriction: Do not dispose of the medicine by throwing it away in household waste or wastewater.
  • Procedure: Discard unused or expired product according to local requirements for pharmaceutical waste, typically by consulting a pharmacist or utilizing a drug take-back program.

Connection to the Overall Storage/Disposal Profile:

Regulatory documents define specific constraints for storing Supraneuron, requiring controlled room temperature and protection from environmental factors like light and moisture. This ensures the physical integrity of the tablets. The official guidance also strictly controls disposal, directing that products be discarded via appropriate pharmaceutical-waste channels rather than general trash or drainage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Supraneuron found in:

A-Z Index: